Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer

Clinical Genitourinary Cancer

Volumn 9, Issue 2, 2011, Pages 89-94

  Scholz, Mark C ^a,b   Lam, Richard Y ^a   Strum, Stephen B ^c   Labarba, Dean J ^a   Becker, Lauren K ^a   Chang, Patricia ^a   Farhoumand, Nojan ^a   Jennrich, Robert I ^d  

^a Prostate Oncology Specialists   (United States)

^b Prostate Cancer Research Institute   (United States)

^c Ashland Community Hospital   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active surveillance; Intermittent androgen deprivation; Survival

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER THERAPY; CONTROLLED STUDY; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; THERAPY DELAY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 80055063696     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.07.002     Document Type: Article

References (26)

1. S.B. Strum Neoadjuvant therapy of early prostate cancer with combination hormonal blockade (CHB) Proc Am Soc Clin Oncol 13 1994 239
2. M.C. Scholz, R.I. Jennrich, and S.B. Strum Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period J Urol 175 2006 1673 1678
3. S.A. Boorjian, R.J. Karnes, and L.J. Rangel Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy J Urol 179 2008 1354 1361
4. T. Pickles, A. Agranovich, and E. Berthelet Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma Cancer 94 2002 362 367 (Pubitemid 34081364)
5. S.B. Strum, M.C. Scholz, and J.E. McDermed Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy Oncologist 5 2000 45 52 (Pubitemid 30127544)
6. J.N. Graff, M. Mori, and H. Li Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study J Urol 177 2007 1307 1312 (Pubitemid 46436011)
7. H. Akaza, Y. Homma, and M. Usami Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up BJUI Int 98 2006 573 579 (Pubitemid 44185879)
8. G.L. Lu-Yau, P.C. Albertsen, and D.F. Moore Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181 (Pubitemid 351969301)
9. R.L. Leibowitz, and S.J. Tucker Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients Oncologist 6 2001 177 182 (Pubitemid 32328005)
10. J. Kawakami, J.E. Cowan, and E.P. Elkin Androgen-deprivation therapy as primary treatment for localized prostate cancer Cancer 106 2006 1708 1714
11. R.J. Segal, R.D. Reid, and K.S. Courneya Resistance exercise in men receiving androgen deprivation therapy for prostate cancer J Clin Oncol 21 2003 1653 1659 (Pubitemid 46638574)
12. M.C. Scholz, and S.B. Strum Re: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial [Letter] J Urol 161 1999 1914 1915
13. B. Guess, M.C. Scholz, and R.Y. Lam Preventing and treating the side effects of testosterone inactivating pharmaceuticals in men with prostate cancer Semin Preventative Alternative Med 2 2006 76 84 (Pubitemid 351193748)
14. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
15. C.S. Saigal, J.L. Gore, and J. Hanley Androgen deprivation therapy increased cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500 (Pubitemid 47463063)
16. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425 (Pubitemid 46999213)
17. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
18. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
19. U.E. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent European Organization for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876 (Pubitemid 46638985)
20. F.H. Schroder, K. Kurth, and S.D. Fossa Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumor: final results of European Organization for the Research and Treatment of Cancer Protocol 30846 after 13 years of follow-up Eur Urol 55 2008 14 22
21. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977 1984 (Pubitemid 40638368)
22. M.P. Wirth, W.A. See, and D.G. McLeod Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer. results from the second analysis of the early prostate cancer program at a median followup of 5.4 years J Urol 172 2004 1865 1870 (Pubitemid 39363075)
23. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
24. P.C. Albertson, D.F. Moore, and W. Shih Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 31 2011 2330 2338
25. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial Lancet 373 2009 301 308
26. Warde PA, Mason MD, Sydes MR, et al. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0220; NCT00002633. Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology. June 4-8, 2010. Chicago, IL. Abstract CRA 4504.